Clave Capital
VC Fund
Pamplona, Spain
Clave Capital is a VC fund in Pamplona focused on Biotechnology and Software. Clave is an investment management company.
- Total investments:
- 48
- Last investment:
- Lead investor:
- 38%
- Fund size:
- $53M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Clave Capital invests in
Stages Clave Capital invests in
Countries Clave Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $462k–$5.5M
- Series A
- $3.2M–$21M
- Venture - Series Unknown
- $541k–$7.1M
Investment Focus
Industry
- Biotechnology 11 (23%)
- Software 7 (15%)
- Health Care 7 (15%)
- Medical Device 5 (10%)
- Artificial Intelligence 5 (10%)
Stage
- Seed 26 (54%)
- Series A 6 (13%)
- Venture - Series Unknown 5 (10%)
- Funding Round 3 (6%)
- Pre-Seed 1 (2%)
Country
- Spain 31 (65%)
- Chile 1 (2%)
- Switzerland 1 (2%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Pedro De Alava
Office Director
|
Office Director | Total investments: 7 | Find email | |
| CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sensesbit
|
Sensesbit is a SaaS market research platform focused on sensory intelligence for the food and beverage industry, developed by TasteLab to analyze and predict product market acceptance . The tool integrates advanced statistical analysis, AI for benchmarking, and computer vision tools to manage sensory testing with consumers and trained panels. Learnmore about the platform on the official Sensesbit website. | $1.1M / Venture - Series Unknown / Jul 15, 2026 | |
Telum Therapeutics
|
Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M / Series A / Jul 01, 2026 | |
D-Sight
|
D-Sight is an early treatment for the leading cause of preventable blindness in the working-age population. | $2.4M / Seed / Feb 23, 2026 | |
Pharmacelera
|
Pharmacelera is a company that applies accurate Quantum-Mechanics (QM) algorithms, Machine Learning (ML) and High-Performance Computing (HPC) to mine an unexploited chemical space and propose molecular candidates that have higher chances to become a drug. The patented computational technology derives from more than 25 years of research at theUniversity of Barcelona and it has been validated in scientific peer-reviewed publications and benchmarking studies performed by our users and customers. | $7.1M / Venture - Series Unknown / Feb 18, 2026 | |
Neboda
|
Neboda is a science and technology that aims to transform agriculture into a more sustainable, competitive, and appealing business while also producing a better and healthier product. | $2.2M / Seed / Jul 21, 2025 | |
Aortyx
|
Aortyx is a pioneer company founded by researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona that aims at providing a new generation of endovascular devices to treat vascular diseases. Our technology focuses on tissue regeneration by mimicking the aorta biomechanical environment. It provides a suitable milieu for cellmigration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta. | $16M / Series A / Jun 12, 2025 | |
Semi Zabala
|
Semi Zabala is a power semiconductor company that uses new technologies to develop, manufacture, qualify, and market semiconductor circuits and devices for use in power electronics for high-performance and reliability applications. | $5.5M / Seed / Jun 05, 2025 | |
Genbioma
|
Evidence-based microbiome company aims to leverage the central role of probiotics and the gut microbiota on the glycemic regulation. "Microbiota" "Premium probiotics" "Long-term glycemic regulation" "Prediabetes" | $540.7K / Feb 11, 2025 | |
|
Genbioma
|
Evidence-based microbiome company aims to leverage the central role of probiotics and the gut microbiota on the glycemic regulation. "Microbiota" "Premium probiotics" "Long-term glycemic regulation" "Prediabetes" | $544.1K / Seed / Feb 11, 2025 | |
Corify Care
|
CORIFY Care is a start-up funded by main world-wide experts on cardiac arrhythmias which is going to introduce in the market a novel medical device to non-invasively map cardiac arrhythmias in real time. This novel technology will improve the treatment in more than 10 million of atrial fibrillation patients only in Europe. Our non-invasiveelectro-anatomical mapping systems displays the activation patterns in each point of the heart without the need of invasive catheters, allowing the possibility to map all atrial fibrillation patients even during a regular visit to the cardiologist. CORIFY Care is located in Madrid, Spain, one of the most attractive places to work/live on the South of Europe. | $3.2M / Venture - Series Unknown / Dec 11, 2024 | |
| See all 48 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Clave Capital invest in?
Clave Capital invests primarily in Biotechnology, Software and Health Care startups, most often at Seed and Series A stage. Most of the 48 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Clave Capital's check size?
Clave Capital typically joins rounds of $462k–$5.5M at Seed, $3.2M–$21M at Series A and $541k–$7.1M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Clave Capital participates in.
How do I contact Clave Capital?
Public channels for Clave Capital include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Clave Capital?
The team at Clave Capital includes Pedro De Alava (Office Director) and Jose Javier Armendariz (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
